| Autor: |
Abbie Oey, Matthew McClure, Julian A Symons, Sushmita Chanda, John Fry, Patrick F Smith, Kathia Luciani, Michael Fayon, Kulkanya Chokephaibulkit, Rattapon Uppala, Jolanta Bernatoniene, Kenji Furuno, Thorsten Stanley, Dymphy Huntjens, James Witek, and RSV2004 Study Groups |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
PLoS ONE, Vol 18, Iss 7, p e0288271 (2023) |
| Druh dokumentu: |
article |
| ISSN: |
1932-6203 |
| DOI: |
10.1371/journal.pone.0288271 |
| Popis: |
Respiratory syncytial virus (RSV) infection is the leading cause of infant hospitalizations and mortality. Lumicitabine, an oral nucleoside analog was studied for the treatment of RSV. The phase 1b and phase 2b studies reported here assessed the safety, pharmacokinetics, and pharmacodynamics of lumicitabine in infants/neonates hospitalized with RSV. In the phase 1b study, infants (≥1 to ≤12 months) and neonates ( |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
